MarketWatch19d agobullish
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
146last 24h
877last 7d
147● bullish (7d)
96● bearish (7d)
214publishers
Investing.com42d agobullish
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuationInvesting.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
24/7 Wall St.44d agobullish
Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to RunEli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.
Motley Fool45d agobullish
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?The stock is up just 8% this year and could prove to be an undervalued buy.
GuruFocus.com55d agobullish
AbbVie Beats but Cuts Guidance on $10.9 Billion AcquisitionRevenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates
Zacks55d agobullish
AbbVie (ABBV) Q2 Earnings and Revenues Beat EstimatesAbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
The Wall Street Journal55d agobullish
AbbVie Lowers Outlook to Account for Acquisition as Profit JumpsAbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
Barrons.com55d agobullish
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
Investor's Business Daily58d agobullish
Botox Maker Tops Buy Point, But Here Comes The Earnings ReportAbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen AbbVie's immunology pipeline.
GuruFocus.com65d agobullish
Biotech IPOs Surge 55% as AI Listings Lose MomentumStrong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.
Investor's Business Daily80d agobullish
Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into EarningsJohnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.
Motley Fool86d agobullish
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?AbbVie knows how to plan ahead.
The Wall Street Journal94d agobullish
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in CashAbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company’s immunology and inflammation portfolio.
Zacks139d agobullish
Ironwood Stock Down Despite Q1 Earnings and Revenue BeatIRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.